|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0891 - 0.0900|
|52 Week Range||0.0616 - 0.3800|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for BVAXF
The Power Play by The Market Herald has announced the release of a new interview with BioVaxys Technology discussing their latest news.
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that in an action that further expands the value of their IP portfolio, the Company has broadened the patent coverage for its viral vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") for BVX-1021, it's vaccine for SARS1 and other sarbecoviruses.
BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of its previously announced non-brokered private placement (the "Private Placement"). Pursuant to the Final Tranche of the Private Placement, the Company has issued 1,350,000 units ("Units") at a price of $0.10 per Unit for gross proceeds of $135,000. Including the first tranche of the Private Placement which completed on August